Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07844551 | ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC | not yet recruiting | Phase 2 | 40 | Huashan HospitalOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07845097 | Phase II Trial Comparing Stereotactic Body Radiotherapy Versus Active Surveillance for Oligometastatic Adenoid Cystic Carcinoma | not yet recruiting | Phase 2 | 90 | All India Institute of Medical SciencesOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07824856 | Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 138 | Sun Yat-sen UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07797881 | A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 60 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 106 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07818486 | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07513324 | Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) | not yet recruiting | Phase 2 | 116 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812467 | Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 220 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07484139 | H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)(NEO COMBAT XL) | not yet recruiting | Phase 2 | 26 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07794488 | Platinum-Free Regimen in Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 145 | Zhejiang Cancer HospitalOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07796126 | Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status(HNSCC) | not yet recruiting | Phase 2 | 22 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07791745 | A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. | not yet recruiting | Phase 2 / Phase 3 | 362 | Taizhou Mabtech Pharmaceutical Co.,LtdINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07788950 | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | not yet recruiting | Phase 2 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07789158 | Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 269 | Fudan UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07780877 | Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer | not yet recruiting | Phase 2 | 85 | Fudan UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07778368 | A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 20 | Shanghai East HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07778732 | Adebrelimab Combined With Dalpiciclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 32 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Aug 21, 2026 | clinicaltrials |
| NCT07766889 | Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07418034 | A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)(SAVED) | not yet recruiting | Phase 2 | 132 | University of Maryland, BaltimoreOTHER | 0 | Aug 14, 2026 | clinicaltrials |
| NCT07552558 | Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) | not yet recruiting | Phase 1 / Phase 2 | 45 | Washington University School of MedicineOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07756190 | Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study(RADIANCE) | not yet recruiting | Phase 2 | 28 | Sun Yat-sen UniversityOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07751276 | Perioperative Finotonlimab Plus Chemotherapy in Untreated Stage II HNSCC | not yet recruiting | Phase 2 | 142 | Yanjie Zhang, MDOTHER | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07751289 | Anti-PD-1 Therapy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma(neo-Recur) | not yet recruiting | Phase 2 | 217 | Yanjie Zhang, MDOTHER | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07677475 | MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 65 | Dongguan People's HospitalOTHER_GOV | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07470489 | Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer | not yet recruiting | Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07064902 | Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07521670 | Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)(STRAP) | not yet recruiting | Phase 2 | 68 | National Cancer Centre, SingaporeOTHER | 4 | Jul 15, 2026 | clinicaltrials |
| NCT07662720 | A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer(MORALE-HN01) | not yet recruiting | Phase 1 / Phase 2 | 18 | Glycyx TherapeuticsINDUSTRY | 0 | Jul 15, 2026 | clinicaltrials |
| NCT07578467 | Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs | not yet recruiting | Phase 1 / Phase 2 | 35 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT07682675 | Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck(ZANACC) | not yet recruiting | Phase 2 | 51 | UNICANCEROTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07683507 | Becotatug Vedotin Plus PD-1 Inhibitor for Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | Feng LiuOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07679997 | Trilaciclib Combined With Immunochemotherapy for R/M HNSCC | not yet recruiting | Phase 2 | 32 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 1, 2026 | clinicaltrials |
| NCT07645846 | Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal Carcinoma(PANDA) | not yet recruiting | Phase 2 | 23 | Sun Yat-sen UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07659678 | CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 90 | Washington University School of MedicineOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07303283 | Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 140 | Kai HuOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07630363 | PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | not yet recruiting | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07628062 | Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation | not yet recruiting | Phase 2 | 70 | ImmunityBio, Inc.INDUSTRY | 0 | Jun 4, 2026 | clinicaltrials |
| NCT07616141 | Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic Carcinoma(NAET4-SNACC) | not yet recruiting | Phase 2 | 76 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07589049 | Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study(GATEWAY) | not yet recruiting | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07567742 | Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 130 | Sun Yat-sen UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07565389 | Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma(AK112) | not yet recruiting | Phase 2 | 42 | National University Hospital, SingaporeOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07535567 | Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma(NimoBenSeq) | not yet recruiting | Phase 2 / Phase 3 | 386 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 0 | Apr 30, 2026 | clinicaltrials |
| NCT07555860 | Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 28 | Sun Yat-sen UniversityOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT07554768 | Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC(RAIN-HNSCC) | not yet recruiting | Phase 2 | 36 | Chen ChunyanOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07545083 | Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC) | not yet recruiting | Phase 2 | 26 | Shanghai Zhongshan HospitalOTHER | 0 | Apr 22, 2026 | clinicaltrials |
| NCT07529873 | Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma(N'FORCE) | not yet recruiting | Phase 2 | 131 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 0 | Apr 14, 2026 | clinicaltrials |
Data updated 19 hours agoSource updated Sep 29, 2026source: clinicaltrials